Advertisement

Topics

Outcome Company Profile

01:49 EDT 24th September 2018 | BioPortfolio

Outcome is the leading provider of strategies and solutions designed to meet the unique needs of the post-approval market. The Company focuses on program strategy and the practical deployment of registries, Phase IV studies, and risk management programs, including the application of state-of-the-art technology to better achieve the unique goals and requirements of the post-approval phase.Outcome's market-leading technology is distinguished by its scalability, performance and reliability. Additionally, the technology requirements of post-marketing programs are different than those of pre-approval trials. Ease of use, faster response times, better reporting and more value added features are critical for success.
Backed by expertise and experience in over 30 therapeutic areas, Outcome has designed, developed and managed an industry leading number of post-approval studies including more than 60 registries. These include many of the largest and most well-recognized programs for disease outcomes and safety/risk management. An Outcome registry has also received a 2004 Innovation Award from the Department of Health and Human Services. With more than 1 million patients enrolled in studies powered by Outcome and over 3,000 sites logging on to the Outcome system daily, the Company has by far the most widely used system in the industry. Outcome is headquartered in Cambridge, Mass.

Location

201 Broadway
Cambridge
Massachusetts
02139
United States of America

Contact

Phone: (617) 621-1600
Fax: (617) 621-1620
Email: info@outcome.com


News Articles [10 Associated News Articles listed on BioPortfolio]

Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA

FDA Confirms Vitaros Regulatory Pathway  Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Ap...

SIGA Technologies Announces Favorable Outcome of Advisory Committee In Support of TPOXX®

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a health security company specializing in the development and commercialization of solutions for serious u...

Pacific Biosciences Announces Favorable Outcome in UK and German Patent Litigation Against Oxford Nanopore

MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that it has entered ...

INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray

PHOENIX, May 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...

ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation

Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as poten...

Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD

HONOR Study will Stop due to Inadequate Separation from Placebo at Week-12 Results at Week-4 Demonstrated Meaningful Clinical Improvement Company Plans to Meet with FDA to Discuss Next Steps for ...

Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

FREMONT, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and c...

Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

FREMONT, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Cedax [Pernix Therapeutics, LLC]

CEDAX (ceftibuten capsules) and (ceftibuten for oral suspension)

PubMed Articles [17 Associated PubMed Articles listed on BioPortfolio]

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.

After coronary artery bypass graft (CABG) surgery in individuals with type 2 diabetes, there remains a considerable residual cardiovascular risk. In the EMPA-REG OUTCOME® trial in participants with t...

SUCCESSFUL SURGICAL OUTCOME OF FULL-THICKNESS MACULAR HOLE WITH CHOROIDAL COLOBOMA.

To report a case of successful closure of macular hole after surgery in a patient with choroidal coloboma.

OUTCOME OF ENDOVASCULAR PROCEDURES ON OCULAR FINDINGS IN TAKAYASU ARTERITIS.

To evaluate the outcome of endovascular procedures on ocular findings in patients with Takayasu arteritis.

SERUM ELECTROLYTES AND OUTCOME IN PATIENTS UNDERGOING ENDOSCOPIC GASTROSTOMY.

Percutaneous endoscopic gastrostomy (PEG) is a gold standard for long term enteral feeding. Neurologic dysphagia and head/neck cancer are the most common indications for PEG as they can lead to protei...

ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: AN INDEPENDENT ANALYSIS OF PROTOCOL I STUDY DATA.

This post hoc analysis explores the relationship between early retinal anatomical response and long-term anatomical and visual outcomes with ranibizumab in center-involved diabetic macular edema.

Clinical Trials [29 Associated Clinical Trials listed on BioPortfolio]

Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

Purpose: The overall hypothesis of the study is that the benefits attained in the EMPA-OUTCOME were, at least in part, mediated by a glucose-independent mechanism. Thus, to demonstrate th...

Patient-reported Outcome Scale in Acute Pancreatitis

The PAN-PROMISE study (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis-an international proSpEctive cohort study) aims to measure an outcome variable in acute pancreatitis (AP) based ...

Comparing Program Options for Latinos With Diabetes

BACKGROUND AND SIGNIFICANCE: Diabetes is a national health problem, yet Latinos from low-income households are at greater risk. Although guidelines recommend that patients learn self-mana...

EMPA Acute Heart Failure

In this study the investigators are aiming to treat patients with acute heart failure with or without diabetes with Empagliflozin or placebo. Given the beneficial effects of Empagliflozin ...

Comparative Effectiveness of Empagliflozin in the US

Empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, was launched as a treatment for type 2 diabetes mellitus (T2DM) in the U.S. in August 2014. In contrast with several pr...

Companies [8 Associated Companies listed on BioPortfolio]

Outcomes Pharmaceutical Health Care

Outcome is the leading provider of patient registries, studies, quality improvement programs, and integrated technologies for evaluating real-world outcomes. Outcome provides serv...

Outcome

Outcome is the leading provider of strategies and solutions designed to meet the unique needs of the post-approval market. The Company focuses on program strategy and the practical deployment of regis...

Outcome Sciences, Inc.

Outcome is the leading provider of patient registries, studies, quality improvement programs, and integrated technologies for evaluating real-world outcomes. Outcome provides serv...

NeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical AB (www.neurovive.com) is a Swedish drug development company whose primary mission is to develop drugs for the treatment of acute brain injury, reperfusion injury in myocard...

N.C. Stroke Association

NCSA is a 501 (c) 3 organization founded in 1998 by a group of physicians and lay people who saw the need to address the state’s increasing prevalence of stroke and it...

More Information about "Outcome" on BioPortfolio

We have published hundreds of Outcome news stories on BioPortfolio along with dozens of Outcome Clinical Trials and PubMed Articles about Outcome for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Outcome Companies in our database. You can also find out about relevant Outcome Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record